Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalized antibiotic dosing may boost infection treatment

NCT ID NCT05914467

Disease control Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This study tests whether using personalized dosing (based on drug levels in the blood) for the antibiotic teicoplanin works better than standard dosing for treating bacterial infections. About 74 adults in hospital intensive care or other units will take part. The goal is to see if more patients reach the right drug level faster and have better outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

54 people

The number who actually took part.

Started

Aug 2023

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The patient is admitted to the ICU, haematology, gastroenterology or orthopaedics department. 2. The patient is at least 18 years old on the day of inclusion. 3. The patient is treated with teicoplanin as part of standard care. 4. The patient or a representative is willing to sign the Informed Consent Form Exclusion Criteria: 1. The patient has previously participated in this study. 2. The patient receives any form of renal replacement criteria (RRT) other than CVVHD / CVVHDF. 3. Expected duration of teicoplanin therapy is less than 5 days. 4. The patient is pregnant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bacterial infections are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bacterial infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bacterial infections

Contacts and locations

Locations

  • RadboudUMC

    Nijmegen, 6525GA, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.